Athersys shares are trading lower after the company said it intends to conduct additional data analysis with independent statisticians because the sample size in the Phase 3 MASTERS-2 is insufficiently powered to achieve the primary endpoint.
Portfolio Pulse from Bill Haddad
Athersys announced its intention to conduct additional data analysis with independent statisticians due to the insufficient sample size in the Phase 3 MASTERS-2. This has led to a decrease in the company's share price.
October 10, 2023 | 3:55 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Athersys' announcement of additional data analysis for Phase 3 MASTERS-2 due to insufficient sample size has negatively impacted its share price.
The announcement of additional data analysis indicates potential issues with the Phase 3 MASTERS-2 trial, which could delay the development and approval of the drug. This uncertainty has led to a decrease in Athersys' share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100